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The antifungal susceptibilities of 40 clinical and environmental isolates of A. terreus sensu stricto to amphotericin B, terbin-
afine, itraconazole, and voriconazole were determined in accordance with CLSI document M38-A2. All isolates had itraconazole
and voriconazole MICs lower than epidemiologic cutoff values, and 5% of the isolates had amphotericin BMICs higher than
epidemiologic cutoff values. Terbinafine showed the lowest MICs. No significant differences were found whenMICs of clinical
and environmental isolates were compared.
In recent decades, fungal infections due to Aspergillus specieshave become a major cause of morbidity and mortality among
immunocompromised patients (1–3). Aspergillus fumigatus is the
most frequently isolated species, although there has been an in-
crease in the incidence of other species, including Aspergillus fla-
vus, A. niger, and A. terreus (1, 4, 5).
A. terreus is considered an emerging opportunistic fungus
which can produce superficial to serious invasive infections (4–8).
Invasive infections are often treated empirically with amphoteri-
cin B, a widely used broad-spectrum drug. However, most A. ter-
reus isolates are resistant in vivo and in vitro to this drug (9–13).
Voriconazole has proved to be most effective, in vivo and in
vitro, against this species (14–16), although some publications (9,
17–19) have already reported clinical isolates of A. terreus with
higher MICs than the established epidemiologic cutoff values
(ECVs) for itraconazole and voriconazole (20).
The aim of this study was to determine the antifungal suscep-
tibility profile of clinical and environmental isolates of A. terreus
for amphotericin, terbinafine, and triazole derivatives and moni-
tor the possible emergence of strains with reduced antifungal tri-
azole activity.
A total of 40 isolates of A. terreus complex—19 clinical and 21
environmental—were studied. Environmental isolates were ob-
tained from indoor and outdoor hospital environments and from
soils and trees in Resistencia (27°27=05S, 58°59=12W) and Cor-
rientes (27°30=00S, 58°48=00W) (cities located in northeastern
Argentina). Clinical isolates were obtained from skin and soft tis-
sues samples, bronchoalveolar lavage samples, fingernails, and
toenails.
All of isolates were identified as A. terreus complex according to
general taxonomical keys (21–24).
For molecular identification, DNA extraction was performed
according to the method described by Bosco Borgeat et al. (25)
The partial sequence of the calmodulin (CalM) gene was amplified
under conditions described by Peterson (26), using primers CF1 F
(5=GCCGACTCTTTGACYGARGAR) and CF4 R (5=TTTYTGCA
TCATRAGYTGGAC). PCR products were purified using Pure-
Link quick PCR purification kit (Invitrogen, Germany) following
the supplier’s protocol. PCR products were sent for sequencing to
the Department of Ecology, Genetics and Evolution Sequencing
and Genotyping Service, University of Buenos Aires, Buenos Ai-
res, Argentina, and to the Division of Hygiene and Medical Mi-
crobiology Medical University of Innsbruck, Innsbruck, Austria.
Bidirectional sequencing was performed for all isolates. Sequenc-
ing errors were detected and corrected with BioEdit sequence
alignment editor software, version 7.2.5 (http://www.mbio.ncsu
.edu/bioedit/bioedit.html). All of the isolates were identified as A.
terreus sensu stricto.
MICs were determined by broth microdilution method in ac-
cordance with the Clinical and Laboratory Standards Institute
(CLSI) document M38-A2 (27).
Antifungal activities were determined for voriconazole (Pfizer,
USA), itraconazole (Sigma-Aldrich, Argentina), terbinafine (Sig-
ma-Aldrich, Argentina), and amphotericin B (Sigma-Aldrich, Ar-
gentina). Solutions were prepared in dimethyl sulfoxide (Sigma-
Aldrich, Argentina) and stored at70°C until they were used. The
final concentrations of all drugs were 0.03 to 16 g/ml.
The quality control strains Candida parapsilosis ATCC 22019,
Candida krusei ATCC 6258, and A. flavus ATCC 204304 were
included in each testing assay (27).
MIC endpoints for amphotericin B, azoles, and terbinafine
were considered the lowest concentrations that produced a com-
plete inhibition of visible growth at 48 h.
The significance of the differences in MICs between clinical
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and environmental isolates was determined by the Student t test
(unpaired, unequal variance). A P value of0.05 was considered
significant.
The MIC ranges, geometric means, modes, MIC50s, and
MIC90s obtained are summarized in Table 1.
A. terreus is a cosmopolitan fungus frequently isolated from
indoor and outdoor environments in northeast Argentina (28). In
addition, it is one of the more frequently opportunistic agents of
onychomycosis isolated in these regions (22).
Clinical breakpoints have not been established for mold
testing. However, epidemiologic cutoff values (ECVs) of and am-
photericin B, itraconazole, posaconazole, and voriconazole are
available for five Aspergillus spp. (among them A. terreus). The
ECV of amphotericin B for A. terreus was defined as 4 g/ml,
encompassing 97.5% of the modeled wild-type population (29),
and the ECVs of itraconazole and voriconazole for A. terreus were
defined as 1 g/ml (20).
The use of voriconazole for the treatment of invasive aspergil-
losis caused by A. terreus improved clinical response of patients
(15, 16, 29, 39). These in vivo results correlate with our in vitro
data; all voriconazole MICs were lower than the ECV (20) for both
clinical and environmental isolates. The same situation was ob-
served for itraconazole; some strains even showed MICs lower
than that for voriconazole. Similar results were reported by other
authors, showing a high in vitro activity of these antifungals (30–
33). In contrast, some reports from European countries and the
United States describe strains of A. terreus with MICs higher than
the ECV for voriconazole and itraconazole (9, 17, 18, 20, 31).
Reports on susceptibility testing of terbinafine have increased
since this antifungal has shown a high activity in vitro against a
broad spectrum of pathogenic fungi (34). This drug showed po-
tent in vitro activity against all isolates of A. terreus tested, with
MICs lower than triazole derivates. These data are consistent with
values published by Moore and Walls, who reported a MIC90 of
0.25g/ml with a range of 0.125 to 1g/ml (11). Garcia-Effron et
al. reported higher values (MIC90, 1g/ml; range, 0.03 to 4g/ml)
(34), although these differences may be due to the different meth-
ods used.
Most investigations show that A. terreus has intrinsic resistance
to amphotericin B, with elevated MICs (4, 9, 14, 32, 34, 35). In our
study, 95% (38/40) of all isolates exhibited amphotericin B MICs
of4g/ml. Only two isolates (one clinical and one environmen-
tal) showed amphotericin B MICs of 8g/ml, above the proposed
ECV (29). On the other hand, some studies have reported strains
with low MICs (1g/ml) for this drug (18, 30, 31, 36). Only 4/19
clinical isolates and 8/21 environmental isolates showed ampho-
tericin B MICs of 1g/ml in our study. These findings suggest that
there may be A. terreus sensu stricto strains that are susceptible to
amphotericin B, but more research is needed to know if these
isolates represent variants with susceptibility to amphotericin B.
No statistically significant differences between the susceptibil-
ity data obtained for clinical and environmental isolates were ob-
served, as reported by other authors (30, 37), although Araujo et
al. (38) found environmental isolates with significantly higher
MICs than clinical isolates for amphotericin B.
Antifungal susceptibility testing is essential in patient manage-
ment and surveillance of resistance. Little is known about the
susceptibility profile of A. terreus worldwide. The present study is
a contribution to the knowledge of the susceptibility of this op-
portunistic fungus and shows that A. terreus sensu stricto isolates
obtained in this region have low MICs for itraconazole, voricona-
zole, and terbinafine and exhibit high amphotericin B MICs.
Nucleotide sequence accession numbers. Sequences of the
CalM genes of the 40 A. terreus isolates have been submitted to the
European Nucleotide Archive (ENA) and assigned the accession
numbers LN734824 to LN734863 (http://www.ebi.ac.uk/ena/data
/view/LN734824-LN734863).
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